Young-Woong Won

Young-Woong Won

Auto-generated profile, based on publicly available information

Young-Woong Won

Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Lung Cancer
Verified
Journal Article
Closed access
YWYoung-Woong Won
Young-Woong Won
JJJungnam Joo
Jungnam Joo
TYTak Yun
Tak Yun
GLGeon-Kook Lee
Geon-Kook Lee
JHJi-Youn Han
Ji-Youn Han
SKSohee Kim
Sohee Kim

1 July 2011 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
YWYoung-Woong Won
Young-Woong Won
JHJi-Youn Han
Ji-Youn Han
GLGeon Kook Lee
Geon Kook Lee
SPSeog-Yun Park
Seog-Yun Park
KLKun Young Lim
Kun Young Lim
JLJin Soo Lee
Jin Soo Lee
Aims: Deletion of exon 19 of the epidermal growth factor receptor (EGFR) and mutation of exon 21 are the most common EGFR mutations and predict higher response to EGFR tyrosine kinase inhibitors (TKI). Accumulating data show clinical differences in both response and survival between these two EGFR mutations. This study investigated the clinical impact of EGFR exon 19 deletion and L858R mutation by retrospectively analysing the clinical outcome of patients with advanced non-small-cell lung cancer (NSCLC) treated with EGFR TKI. Methods: Patients harbouring EGFR exon 19 deletion or L858R mutations and who had received gefitinib or erlotinib treatment were identified. The response rate (RR), progression-free survival (PFS) and overall survival (OS) were determined for the two groups. EGFR mutation was determined by PCR-based direct sequencing. Results: The study indentified 87 patients harbouring EGFR exon 19 deletion (n=61) or L858R mutation (n=26) who were treated with either gefitinib (n=83) or erlotinib (n=4). Patients with exon 19 deletion had significantly longer PFS, compared with patients with L858R mutation (9.3 vs 6.9 months, p=0.02). In a multivariate Cox regression model, EGFR exon 19 deletion was independently predictive of longer PFS (p=0.02). However, no significant differences in RR (64% vs 62%, p=0.83) and OS (17.7 vs 20.5 months, p=0.65) were observed between these two mutations. Conclusions: While no significant difference in OS was observed between EGFR exon 19 deletion and L858R mutation, EGFR exon 19 deletion was predictive of longer PFS following EGFR TKI treatment in patients with advanced NSCLC.

11 February 2012 in APMIS
Verified
Journal Article
Open access
PDF file
JCJung‐Hye Choi
Jung‐Hye Choi
JYJin Sun Yoon
Jin Sun Yoon
YWYoung‐Woong Won
Young‐Woong Won
BPByeong‐Bae Park
Byeong‐Bae Park
YLYoung Yiul Lee
Young Yiul Lee
Autophagy is a conserved catabolic process that degrades cytoplasmic proteins and organelles for recycling. The role of autophagy in tumorigenesis is controversial because autophagy can be either protective or damaging to tumor cells, and its effects may change during tumor progression. A number of cancer cell lines have been exposed to chloroquine, an anti‐malarial drug, with the aim of inhibiting cell growth and inducing cell death. In addition, chloroquine inhibits a late phase of autophagy. This study was conducted to investigate the anti‐cancer effect of autophagy inhibition, using chloroquine together with 5‐fluorouracil (5‐FU) in a colon cancer cell line. Human colon cancer DLD‐1 cells were treated with 5‐FU (10 μΜ) or chloroquine (100 μΜ), or a combination of both. Autophagy was evaluated by western blot analysis of microtubule‐associated protein light chain3 (LC3). Proliferative activity, alterations of the cell cycle, and apoptosis were measured by MTT assays, flow cytometry, and western blotting. LC3‐II protein increased after treatment with 5‐FU, and chloroquine potentiated the cytotoxicity of 5‐FU. MTT assays showed that 5‐FU inhibited proliferation of the DLD‐1 cells and that chloroquine enhanced this inhibitory effect of 5‐FU. The combination of 5‐FU and chloroquine induced G1 arrest, up‐regulation of p27 and p53, and down‐regulation of CDK2 and cyclin D1. These results suggest that chloroquine may potentiate the anti‐cancer effect of 5‐FU via cell cycle inhibition. Chloroquine potentiates the anti‐cancer effect of 5‐FU in colon cancer cells. Supplementation of conventional chemotherapy with chloroquine may provide a new cancer therapy modality.

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JYJun Ho Yi
Jun Ho Yi
BPByeong-Bae Park
Byeong-Bae Park
JKJung Hun Kang
Jung Hun Kang
IHIn Gyu Hwang
In Gyu Hwang
DSDong Bok Shin
Dong Bok Shin
SPSe Hoon Park
Se Hoon Park
AIM: To investigate the clinicopathologic features of patients with extra-gastrointestinal stromal tumors (EGISTs) in South Korea. METHODS: A total of 51 patients with an EGIST were identified. The clinicopathologic features, including sex, age, location, tumor size, histology, mitotic rate, immunohistochemical features, genetic status and survival data, were analyzed. RESULTS: The median age was 55 years (range: 29-80 years), and male:female ratio was 1:1.04. The most common site was in the mesentery (n = 15) followed by the retroperitoneum (n = 13) and omentum (n = 8). The median tumor size was 9.0 cm (range: 2.6-30.0 cm) and the median mitotic rate was 5.0/50HPF. (1/50 - 185/50). KIT was analyzed in 16, which revealed 10 cases with wild-type KIT and 6 cases with an exon 11 mutation. Among 51 patients, 31 patients had undergone surgery, and 10 had unresectable disease and had taken palliative imatinib, which resulted in 22.7 mo of progression-free survival. Of the patients who had undergone surgery, 18 did not take adjuvant imatinib, and 8 of these were categorized as “high risk” according to the risk criteria. However, the relapse-free survival was not different (P = 0.157) between two groups. CONCLUSION: Because the biologic behaviors of GISTs differ according to the location of the tumor, a more stratified strategy is required for managing EGISTs including incorporation of molecular features.

25 January 2007 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
SHSang Youb Han
Sang Youb Han
YWY.-W. Won
Y.-W. Won
JYJ.-H. Yi
J.-H. Yi
HKH.-J. Kim
H.-J. Kim
Renin-angiotensin system (RAS) blockades, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are well accepted for the cardiorenal-protective benefits added to antihypertensive effects in chronic kidney diseases (CKD), but associated with an increased risk of hyperkalaemia. However, few studies have investigated the effect of RAS blockades on serum potassium in dialysis patients. Hyperkalaemia associated with RAS blockades by ACEI and/or ARB was evaluated in 69 patients on maintenance haemodialysis, who underwent a three-period crossover study in four groups (no exposure to RAS blockades, ACEI or ARB alone and ACEI plus ARB treatments), lasting one month in each period. Sixty-two patients completed this prospective 3-month study, and no one stopped the study because of the development of hyperkalaemia and/or complications. Mean serum K was similar among the four periods (no exposure, 5.54+/-0.67 mmol/l; ACEI alone, 5.54+/-0.75 mmol/l; ARB alone, 5.50+/-0.66 mmol/l; ACEI+ARB combination, 5.42+/-0.66 mmol/l) and was also equal when compared between the two groups with and without exposure to RAS blockades (5.48+/-0.68 vs 5.54+/-0.67 mmol/l, P=NS). The incidence of severe hyperkalaemic episodes (>6.0 mmol/l) upon monthly predialysis serum K determination was 25.8% with no exposure to RAS blockades, 29.8% for ACEI alone, 19.6% for ARB alone and 17.7% for ACEI+ARB combination without statistically significant differences among the four periods (P=NS). Among covariables, the degree of Kt/V, intakes of other medications interfering with potassium homeostasis and diabetes mellitus did not result in any significant hyperkalaemic changes during the 3-month study period except anuric patients compared with non-anuric patients (5.58+/-0.69 vs 5.19+/-0.65 mmol/l, P<0.001). Neither monotherapy (ACEI or ARB) nor combination therapy (ACEI plus ARB) is associated with the additional risk of hyperkalaemia in patients on maintenance haemodialysis. However, those patients with anuria on RAS blockades warrant the cautious monitoring of serum K to prevent hyperkalaemia.

1 January 2005 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
YWYoung-Woong Won
Young-Woong Won
WMWon Moon
Won Moon
YYYeong-Seop Yun
Yeong-Seop Yun
HOHo-Suk Oh
Ho-Suk Oh
JCJung-Hye Choi
Jung-Hye Choi
MAMyung-Ju Ahn
Myung-Ju Ahn
Idiopathic thrombocytopenic purpura (ITP) is a condition that often develops in young women and, consequently, physicians should frequently manage and monitor pregnant patients with this disorder. We reviewed the charts of 30 women with chronic ITP delivered in 31 pregnancies from January 1995 to December 2003. Fifteen patients were diagnosed with ITP before pregnancy and sixteen patients were diagnosed during pregnancy. The mean platelet counts before pregnancy, during pregnancy, and at delivery were 70,040/mm3, 83,960/mm3, and 62,680/mm3, respectively. The symptoms of hemostatic impairment were not noted in most of the pregnancies (77%, 24/31). During pregnancy and at delivery, most of the women (61%, 19/31) received various kinds of treatment to raise platelet counts. At delivery, the most commonly used therapy was platelet transfusion (48.4%, 15/31). Seven pregnancies (22.6%) were treated with corticosteroids during pregnancy and at delivery. Five pregnancies (16.1%) were treated with IV IgG during pregnancy and at delivery. Fifteen deliveries (51.7%) were performed by cesarean section and fourteen (48.3%) with vaginal delivery. Bleeding was uncommon at delivery. There were no cases of infants with any clinical signs of hemorrhage. Our current results suggest that ITP in pregnancy can proceed safely with low hemorrhagic risk in both infants and mothers, and that mothers with ITP can deliver healthy infants without serious hemorrhagic complications